<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03102489</url>
  </required_header>
  <id_info>
    <org_study_id>BP101-HV02</org_study_id>
    <nct_id>NCT03102489</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP101 After Multiple Doses Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ivix LLX</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ivix LLX</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy&#xD;
      Volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind, randomized, placebo-controlled study of the safety, tolerability,&#xD;
      pharmacokinetics and pharmacodynamics of BP101 after multiple doses administration in healthy&#xD;
      volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2017</start_date>
  <completion_date type="Actual">September 19, 2017</completion_date>
  <primary_completion_date type="Actual">June 21, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent Adverse Events</measure>
    <time_frame>6 weeks</time_frame>
    <description>To evaluate frequency, seriousness, and severity of adverse events, including events of dose-limiting toxicity in healthy volunteers receiving different doses of BP101 compared to placebo after multiple administrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BP101 maximum plasma concentration (Cmax)</measure>
    <time_frame>Day 1</time_frame>
    <description>To determine pharmacokinetic parameter of maximum plasma concentration (Cmax) after single administration of BP101 in healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP101 area under the concentration versus time curve (AUC)</measure>
    <time_frame>Day 1</time_frame>
    <description>To determine pharmacokinetic parameter area under the plasma concentration versus time curve (AUC) after single administration of BP101 in healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP101 time to maximum plasma concentration (Tmax)</measure>
    <time_frame>Day 1</time_frame>
    <description>To determine pharmacokinetic parameter time to maximum plasma concentration (Tmax) after single administration of BP101 in healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP101 half-life time (T1/2)</measure>
    <time_frame>Day 1</time_frame>
    <description>To determine pharmacokinetic parameter of plasma half-life time (T1/2) after single administration of BP101 in healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Female Sexual Function Index score</measure>
    <time_frame>2 weeks</time_frame>
    <description>To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Function Index (FSFI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Female Sexual Function Index score</measure>
    <time_frame>6 weeks</time_frame>
    <description>To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Function Index (FSFI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Female Sexual Distress Scale-Revised score</measure>
    <time_frame>2 weeks</time_frame>
    <description>To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Distress Scale-Revised (FSDS-R).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Female Sexual Distress Scale-Revised score</measure>
    <time_frame>6 weeks</time_frame>
    <description>To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Distress Scale-Revised (FSDS-R).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Female Sexual Function questionnaire score</measure>
    <time_frame>2 weeks</time_frame>
    <description>To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Function (FSF) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Female Sexual Function questionnaire score</measure>
    <time_frame>6 weeks</time_frame>
    <description>To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Function (FSF) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Arizona Sexual Experience Scale score</measure>
    <time_frame>2 weeks</time_frame>
    <description>To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Arizona Sexual Experience Scale (ASEX) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Arizona Sexual Experience Scale score</measure>
    <time_frame>6 weeks</time_frame>
    <description>To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Arizona Sexual Experience Scale (ASEX) questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hypoactive Sexual Desire Disorder(HSDD)</condition>
  <arm_group>
    <arm_group_label>BP101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with BP101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BP101</intervention_name>
    <description>Nasal spray</description>
    <arm_group_label>BP101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Nasal spray</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy women aged from 18 to 40, inclusive.&#xD;
&#xD;
          -  Verified diagnosis &quot;healthy&quot;: absence gastrointestinal, hepatic, renal,&#xD;
             cardiovascular, endocrine, central nervous system, ear, nose, throat (ENT) and&#xD;
             gynecological disorders (performed standard clinical, laboratory and instrumental&#xD;
             assessments did not reveal any disorders).&#xD;
&#xD;
          -  Body mass index (BMI) within range from 18.5 to 30 kg/m^2.&#xD;
&#xD;
          -  Subject consent not to intake alcohol during the entire study period; negative alcohol&#xD;
             breath test at screening and before start of Investigational Product administration.&#xD;
&#xD;
          -  Negative pregnancy test result at screening and before start of Investigational&#xD;
             Product administration.&#xD;
&#xD;
          -  Consent to use adequate methods of contraception throughout the study.&#xD;
&#xD;
          -  Normal regular menstrual cycle of 28 +/- 7 days duration for at least 6 months before&#xD;
             study enrollment.&#xD;
&#xD;
          -  Women with stable sexual partner.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic cardiovascular, respiratory, neuroendocrine, genitourinary systems disorders,&#xD;
             as well as gastrointestinal, hepatic, renal, blood, and ENT disorders (including acute&#xD;
             and chronic rhinitis, sinusitis, and others).&#xD;
&#xD;
          -  Gynecological disorders (polycystic ovary syndrome, mommas, endometriosis,&#xD;
             inflammatory diseases and others).&#xD;
&#xD;
          -  Positive cervical cytology Papanicolaou (PAP) test in medical anamnesis within 12&#xD;
             months before screening.&#xD;
&#xD;
          -  Lab abnormalities (blood hematology and biochemistry and urinalysis) at screening.&#xD;
&#xD;
          -  Electrocardiogram (ECG) abnormalities at screening, and before start of&#xD;
             Investigational Product administration.&#xD;
&#xD;
          -  Systolic blood pressure in a sitting position below 100 mm Hg or above 140 mm Hg;&#xD;
             and/or diastolic pressure below 60 mm Hg or above 90 mm Hg at screening and before&#xD;
             start of Investigational Product administration.&#xD;
&#xD;
          -  Heart rate less than 60 beats/min or more than 90 beats/min at screening, and before&#xD;
             start of Investigational Product administration.&#xD;
&#xD;
          -  Signs of malignant neoplasms in medical history, during the examination at any time&#xD;
             prior to start of Investigational Product administration.&#xD;
&#xD;
          -  Psychiatric disorders (including any form of schizophrenia, epilepsy, bipolar&#xD;
             affective disorder and others), intake of psychotropic agents.&#xD;
&#xD;
          -  Chronic pain syndromes (including chronic pelvic pain syndrome).&#xD;
&#xD;
          -  Acute infections within 4 weeks before screening.&#xD;
&#xD;
          -  Regular intake of medications (including nonprescription drugs, vitamins, and&#xD;
             Supplements) within 2 weeks before screening.&#xD;
&#xD;
          -  Intake of more than 5 units of alcohol per week (1 unit of alcohol is equivalent to&#xD;
             0.5 liter of beer, 200 ml wine or 30 ml of spirit (pure alcohol)) or historical&#xD;
             information about alcoholism, substance abuse, prescription drug abuse.&#xD;
&#xD;
          -  Smoking more than 10 cigarettes a day.&#xD;
&#xD;
          -  Pregnancy or breastfeeding, positive urine pregnancy at screening and before the start&#xD;
             of Investigational Product administration.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female healthy volunteers</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniil Nemenov, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ivix LLX</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research center Eco-Safety LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

